MIT-001 for Prevention of CCRT-Induced OM in HNSCC Patients

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

June 21, 2021

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Head and Neck Squamous Cell CarcinomaOral Mucositis
Interventions
DRUG

MIT-001 plus CCRT

MIT-001 IV-infusion plus CCRT

Trial Locations (16)

13620

Seoul National University Bundang Hospital, Gyeonggi-do

14642

James P. Wilmot Cancer Center, Rochester

16247

The Catholic University of Korea Saint Vincent's Hospital, Suwon

27103

Wake Forest Baptist Health - Comprehensive Cancer Center, Winston-Salem

43210

James Cancer Hospital Solove Research Institute, Columbus

54907

Jeonbuk National University Hospital, Jeonju

67208

Cancer Center of Kansas, Wichita

85234

Banner MD Anderson Cancer Center, Gilbert

90033

Norris Comprehensive Cancer Center, Los Angeles

Unknown

Keimyung University Dongsan Hospital, Daegu

Chungnam National University Hospital, Daejeon

National Cancer Center, Goyang-si

Inha University Hospital, Incheon

Hanyang University Seoul Hospital, Seoul

03082

Seoul National University Hospital, Seoul

08308

Korea University Guro Hospital, Seoul

Sponsors
All Listed Sponsors
lead

MitoImmune Therapeutics

INDUSTRY

NCT04651634 - MIT-001 for Prevention of CCRT-Induced OM in HNSCC Patients | Biotech Hunter | Biotech Hunter